utilities were compared to the patient-derived utilities. Treatment data, disease transition probabilities, and hepatitis C related costs were obtained from published literature. The costs of hepatitis C treatments were obtained from an Internet pharmacy. All costs were adjusted to 2004 USD. RESULTS: When patient-reported utilities were used for HCV genotype 1, peginterferon gained 1.28 additional quality-adjusted life years (QALYs) compared with no treatment. The QALYs ranged from 0.71 to 2.35 when expert panel-estimated utilities were employed. For HCV genotype 2 or 3 patients, peginterferon group had 2.72 more QALYs than no treatment using patient-reported utilities. When expert panel-estimated utilities were used for genotype 2 or 3, peginterferon had 1.61 to 4.85 additional QALYs than no treatment. Using patient-derived utilities, the expected costs per QALY for HCV genotype 1 receiving peginterferon and interferon treatment were $2439 and $2335, respectively. For genotype 2 or 3, these costs were $1152 and $1085 per QALY, respectively. The lifetime HCV related cost for patients received no treatment was $1975 per QALY regardless of HCV genotype. CONCLUSION: Many expert panel-estimated utilities provided higher estimates of the benefits, and thus lower cost per QALY, for HCV treatments as compared to patient-reported utilities.

ESTIMATES OF HEALTH CARE COSTS FOR LAMIVUDINE-REFRACTORY CHRONIC HEPATITIS B (CHB) PATIENTS
Tafesse E1, Claxton A2, Granger A2, Sanders J1, Appelain D1, Atillasoy E1, Iloeje U3
1Bristol-Myers Squibb, Wallingford, CT, USA; 2RTI-Health Solutions, Research Triangle Park, NC, USA; 3Harvard University, Brookline, MA, USA; 4Bristol-Myers Squibb, Plainsboro, NJ, USA

For patients with chronic hepatitis B, emergence of lamivudine resistance is associated with poor clinical outcomes, more rapid disease progression and poor quality of life. The clinical implications of lamivudine resistance are well described but the health care costs are not. OBJECTIVE: The objective of this study was to evaluate the health care utilization and direct medical cost within the first year of developing a lamivudine refractory infection in chronic hepatitis B (CHB) patients.

METHODS: Physician estimates of health care utilization for the care of lamivudine refractory CHB patients were collected in a survey of physicians treating CHB patients in the US. A questionnaire was mailed to 165 physicians of which 51 responded. Data on health care utilization was computed for each health care cost category (Physician visits, hospitalizations, diagnostic tests and radiological examinations). Unit costs were derived based on the Medicare Physician Fee Schedule for procedures, the 2002 Health Care Cost and Utilization Project database for inpatient hospitalization costs, and average wholesale prices for medication costs. RESULTS: The total non-drug, direct medical cost within the first year of developing a lamivudine refractory infection in a CHB patient was estimated at $2925. Among the different cost categories diagnostic tests and specialist visits were the major cost drivers, accounting for an estimated 43% and 41% of the overall cost, respectively. Seventy four percent of the patients were estimated to require a specialist visit. Only 2% of patients were estimated to require a hospitalization accounting for a negligible proportion of the costs. CONCLUSION: The estimated non-drug costs for patients refractory to lamivudine represent a substantial economic burden. In addition, the additional costs of rescue therapy further increase the cost impact and make it considerably higher than the annual direct medical cost for CHB patients who do not develop viral resistance.

UTILISATION OF ANTIBIOTICS WITHIN THE SLOVAK REPUBLIC
Tesar T1, Foltan V1, Tomek D1, Visnansky M1
1Comenius University, Bratislava, Slovak Republic; 2Health Insurance fund APOLLO, Bratislava, Slovak Republic; 3Faculty of Pharmacy, Comenius University, Bratislava, Bratislava, Slovak Republic

OBJECTIVES: To analyse the utilisation of antibiotics within the Slovak Republic between 1992 and 2003. Adherence to principles of antibiotic policy lead to fundamental short and long term financial savings within health care systems. METHODS: For 1992–2003, the data of systemic antibiotic use for ambulatory care, aggregated at the level of the active substance, were collected, in accordance with the Anatomic Therapeutic Chemical (ATC) classification and Defined Daily Dose (DDD) measurement unit (WHO). Data of wholesalers, who are legally obliged to provide this information to the Slovak Institute for Drug Control, was used for this detailed analysis of the Slovak consumption of antibiotics. RESULTS: Long term analysis shows that the antibiotic consumption had been increasing in human medicine within Slovakia. In 1992 the consumption of antibiotics at the level of 19.4 DDD/1000/day increased to 28.0 DDD/1000/day in 1999. This analysis focused on the situation in antibiotic consumption in 2001 and 2003 in more detail. The results show that in 2003 as opposed to 2001, the consumption of antibiotics decreased by 900,000 packages. In financial figures can be noticed a increase by 1.75 €/ml, because the average price for one package of antibiotics was at the level of 4.84€ in 2001 but in 2003 the price increased to a level of 5.64€. From our analysis a significant increase in the ATB consumption expressed by DDD/1000/day can be seen (In 2001 it was 25.78 but in 2003 we can see the consumption 26.95 DDD/1000/day). CONCLUSIONS: Inseparable components of the Slovak antibiotic policy must be viewed realistically with regard to the consumption of antibiotics and resistance. Antibiotic resistance is a major public health problem, and antibiotic use is increasingly recognised as the major selective pressure driving this resistance.

IMPROVEMENT IN ANTIMALARIAL DRUGS ACCESS:
RESULTS OF A PROGRAM PERFORMED IN YAOUNDE
N'Do J1, Perard R2, Brun P3
1Cameroon Ministry of Health, Yaoundé, Yaounde, Cameroon; 2Economic University, Marseille, Paris, Paris, France; 3Sanofi-Aventis, Paris, Paris, France

OBJECTIVES: Several studies show that in developing countries, low-income patients use low price counterfeit drugs provided by the illegal drug market. In Cameroon, those false drugs represent 40% of the street market and lead to malaria therapeutic failure and inappropriate medical expenses. The Yaoundé program aims to improve access to efficient antimalarial drugs by providing a differentiated price policy through the official private pharmacy distribution sector, allowing access to efficient antimalarials to low–income population which would otherwise use street market drugs. METHODS: In 31 retail pharmacies of Yaoundé, artesunate (Arsumax®) was made available at a “no profit no loss” public price of 1170FCFA (1.78€) instead of 3400FCFA (5.8€), ie: –66%. Eligibility of patients was based on income below the poverty level (established by the Ministry of Economy as 30€ monthly households incomes per number of dependences). Program effectiveness was assessed by evaluating the number of new patients having access to this lower price Arsumax®. RESULTS: After 6 months of implementation,
patients having access to the lower price Arsumax® increased up to 38% of population buying Arsumax® at normal price (3673 / 9641). During the same period, we notice no consumption decrease for others antimalarials of the same therapeutic group. Patients and pharmacists have strictly observed the program procedures. CONCLUSION: This study shows that a differentiated price policy allows efficient access to high quality antimalarial drugs for low-income population, through the private drug distribution system. Moreover this program is running without any financing support from the government or international funding. Based on this test, the program is being implemented over the entire country and to other African countries.

PIN21

AWARENESS AND KNOWLEDGE OF HPV AMONG UNIVERSITY STUDENTS ATTENDING AN HBCU
Bynum SA, Xiao H
Florida A&M University, Tallahassee, FL, USA
HPV is currently the most common sexually transmitted disease in the United States. It is highly prevalent among sexually active men and women, affecting 20 million people with 5.5 million new cases occurring yearly. About 75% of sexually active individuals will acquire the infection at some point during their lifetime. The highest rates of genital HPV infection have consistently been found in sexually active college age population (20–24-age bracket). OBJECTIVES: To assess knowledge of HPV among students attending an HBCU and to test the effectiveness of an educational intervention program. METHOD: The participants for this research project were 3rd year Pharm.D college students enrolled at a HBCU in Florida. The design was repeated measures with an intervention versus control group. A general knowledge HPV survey was administered to assess HPV knowledge. T-tests were used to analyze the data. RESULTS: Eighty-six percent of the population had heard of HPV. Knowledge of HPV was generally low; out of 6 questions posed only 2 were answered correctly by more than 70% of the population. Education was effective in increasing knowledge of HPV (t[50] = 4.53, p = 0.000). CONCLUSIONS: Awareness of HPV in this population was high but knowledge was low. Simple educational material is effective in increasing knowledge of HPV.

PIN22

HOSPITALIZED COMMUNITY ACQUIRED PNEUMONIA: A THREE YEAR REVIEW OF PATIENT FACTORS ASSOCIATED WITH PROLONGED LENGTH OF STAY
DePestel DD1, Detloff R7, Wolfe T1, Townsend K4, DeLor B3, Giannamore M8
1University of Michigan Health System, Ann Arbor, MI, USA; 2Pfizer; Rockford, MI, USA; 3Pfizer, Westerville, OH, USA; 4Pfizer, Chelsea, MI, USA; 5Pfizer, Hartland, MI, USA; 6Pfizer, Dublin, OH, USA

OBJECTIVES: The primary objective of this analysis was to identify factors associated with prolonged length of stay (LOS) in patients with hospitalized community acquired pneumonia (CAP). METHODS: Data were collected retrospectively on 1861 randomly selected patients with a discharge ICD-9 diagnosis of CAP who were admitted between October 2000 and April 2003 to 29 hospitals in the Great Lakes region. A standardized electronic database was used to collect demographic and clinical data. Logistic regression analysis was used to adjust for potential confounding variables and to identify patient factors associated with a LOS greater than 4 days (cohort median). Pneumonia Severity Index Score (PSI) defined risk class. Antibiotic selection was evaluated relative to standard guidelines (Infectious Diseases Society of America). RESULTS: Patient factors associated with a LOS greater than 4 days included admission during the 2001–2002 season (OR, 1.35; 95% CI, 1.06–1.72), increasing age (OR, 1.01; 95% CI, 1.00–1.02), Risk Class III (OR, 1.50; 95% CI, 1.10–2.06), Risk Class IV (OR, 1.67; 95% CI, 1.20–2.32), Risk Class V (OR, 3.01; 95% CI, 2.0–4.76), ICU admission for pneumonia (OR, 2.11; 95% CI, 1.31–3.40), gram-negative sputum culture (OR, 2.15; 95% CI, 1.37–3.38), gram-positive blood culture (OR, 2.01; 95% CI, 1.28–3.17), increasing hours to antibiotic administration (OR, 1.02; 95% CI, 1.01–1.04), modification of empiric antibiotic regimen (OR, 1.45; 95% CI, 1.17–1.81) and intravenous to oral antibiotic conversion (OR, 2.01; 95% CI, 1.63–2.48). Administration of antibiotic regimens consistent with IDSA guidelines was associated with reduced odds for a longer LOS (OR, 0.50; 95% CI, 0.33–0.77). CONCLUSIONS: Several factors were associated with a hospital LOS greater than 4 days. Guideline-compliant antibiotic use was associated with reduced odds for a long LOS. These findings may facilitate further research and the development of targeted management strategies to control LOS and ultimately resource consumption.

PIN23

ARE SUBJECTS ENROLLED IN CANDIDEMIA CLINICAL TRIALS REPRESENTATIVE OF MOST HOSPITALIZED PATIENTS WITH THIS DISORDER
Sharma R1, Rege M2, Kachroo S3, Garey KW2
1Baylor University, Houston, TX, USA; 2University of Houston, College of Pharmacy, Houston, TX, USA

OBJECTIVE: Clinical trials results are used to guide empiric antifungal therapy. However, how subjects enrolled into clinical trials compare to “real-world” patients is unclear. The purpose of this study was to compare the inclusion/exclusion criteria from published candidemia trials to hospitalized patients with candidemia at our institution. METHODS: The inclusion/exclusion criteria from two large, randomized trials of candidemia (N Engl J Med 1994;331:1225–30 and Clin Infect Dis 2003;36:1221–8) were assessed for 86 patients hospitalized with candidemia between 2002 to 2004 at our institution. Variables collected included APACHEII, vitals, receipt of antifungals, past medical and hospitalization history including hematologic cancer, HIV, burns, allergy, organ transplantation, previous candidemia and laboratory values including bilirubin and liver function tests. Inclusion/exclusion criteria from the published clinical trial were compared to results from our patient population. Percent of patients that would be eligible for study entry were calculated. RESULTS: Seventy-nine percent of our patients would have been excluded from the clinical trials. The most common exclusion criteria included receipt of amphotericin before identification of candida (42%), laboratory abnormalities including elevated bilirubin (15%) and elevated aminotransferases (2%), organ transplantation (8%) or HIV (3%). No patients were excluded due to pregnancy, burns, allergies, other investigational agents, or congenital immunodeficiency syndrome. If it were possible to include patients before receipt of antifungals, 51% of patient would have been able to be enrolled in the study. Apachelli scores were similar in published clinical trials (16.1) compared to our patient population (17.3). CONCLUSION: Subjects enrolled into candidemia clinical trials were similar to our patient population including severity of illness. Exclusion criteria generally involve laboratory safety parameters or different patient populations. Results from these clinical trials are applicable to “real-world” patients.